凯尔·多诺霍在2021年3月被诊断为胶质母细胞瘤（glioblastoma）并被预估寿命约1年。作为罕见的“长期生存者”，她在接受标准手术后化疗和放疗、同年12月出现复发，并于2022年2月接受单次CAN-3110病毒治疗后，肿瘤在首次随访显著缩小，随后几个月消失；截至报道时几乎已接近5年且每3个月MRI持续清晰。文章强调这类个例并非纯粹统计异常，而是提示肿瘤生物学中仍有可被利用的关键机制，也推动了对预后“逆转”者（outliving prognosis）的系统化研究。

从传统“局部切除+放疗+化疗”思路转向神经网络视角后，研究者认为胶质母细胞瘤并非静态肿块，而是与邻近神经元形成突触样连接，借助电化学信号扩散、生长并逃避免疫。多项基础研究指出其可重塑神经样网络，导致手术、化疗、放疗和免疫治疗的获益常仅“有限”；即使在德国的前沿团队中，也观察到“类大脑”管样通道和节律细胞（pacemaker）样功能可驱动整体肿瘤活动。基于这一模型，威克勒团队正在进行3项多中心临床研究：perampanel阻断肿瘤-神经突触、meclofenamate阻断细胞间通讯、senicapoc联合放疗靶向离子通道，若成功可能是20年来该病最重要进展。

Monje与Winkler的研究还拓展到全身癌症：已有证据显示神经纤维和电信号可能参与胃、前列腺和肺等肿瘤生长，提示肿瘤-神经互作可能是更广泛规律。两人2025年共同获得Brain Prize（130万欧元，约合150万美元）后，研究重点转向如何安全抑制促进肿瘤节律的电流。Winkler仅在5名远期生存者中观察到明确模式：确诊后长期保持冷静、规律冥想/绘画/音乐等放松行为，支持情绪状态可能影响肿瘤神经动力学；并非决定性证据，但与文献中肾上腺素、去甲肾上腺素、皮质醇促进应激相关肿瘤复发的机制一致。Chiocca的试验还发现更长期生存患者常伴更高T细胞浸润；而Donohue的生存轨迹正在被用于指导更有针对性的下一代治疗设计。

The article presents a rare but clinically important pattern: glioblastoma is often a near-terminal diagnosis, yet some patients outlive early survival estimates, showing that this is not always statistical noise. Kyle Donohue, diagnosed in March 2021 at age 56 and initially given about one year to live, had surgery, chemotherapy, and radiation, recurred in December 2021, then received a one-time CAN-3110 herpes-virus trial infusion in February 2022; her first follow-up showed shrinkage and later scans showed disappearance, with clear MRIs every three months nearly five years later. This case, and others like it, is driving systematic study of “long-term survivors” to identify biological factors that can be translated into treatment.

Research highlighted a shift from viewing glioblastoma as a localized mass to treating it as a neural-like adaptive system. Work by Michelle Monje and Frank Winkler suggests tumor cells connect directly to neurons, using electrical and chemical signaling to spread and evade immune control; this helps explain why even aggressive surgery, chemotherapy, radiation, and immunotherapies have only modest effects. Their teams describe pacemaker-like tumor cells and ultra-thin signaling tubules, and blocking these networks in mice disrupted growth. In Germany, three multicenter trials now test perampanel, meclofenamate, and senicapoc plus radiation, aiming to disconnect malignant neural circuitry; success could represent the first major therapeutic advance in about two decades. (Key numbers: 3, 20)

The article also frames glioblastoma in a broader cancer-neuroscience context. Monje and Winkler’s 2025 Brain Prize (1.3 million euros, about 1.5 million USD) reflects a growing view that neuronal signaling may regulate tumors in the stomach, prostate, and lungs as well. A mechanistic hypothesis under exploration is that patient emotional state alters neural activity that drives tumor biology: in a small observed sample of five long-term survivors, calm behavior and relaxation practices were common from diagnosis onward. This aligns with broader evidence that stress hormones can promote growth and relapse, while high chronic stress can suppress immunity; Chiocca’s trial notes longer-surviving glioblastoma patients often had higher T-cell counts, though causality remains unproven.